
Molecule: OTELIXIZUMAB
ChEMBL ID: CHEMBL1743053
Mechanism of Action: BINDING AGENT
Max Phase: 3.0
Molecule Type: Antibody

Molecule: TEPLIZUMAB
ChEMBL ID: CHEMBL1743078
Mechanism of Action: OTHER
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2022

Molecule: VISILIZUMAB
ChEMBL ID: CHEMBL2108811
Mechanism of Action: INHIBITOR
Max Phase: 3.0
Molecule Type: Antibody

Molecule: ERTUMAXOMAB
ChEMBL ID: CHEMBL2108029
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 2.0
Molecule Type: Antibody

Molecule: HOKT3
ChEMBL ID: CHEMBL2109253
Mechanism of Action: INHIBITOR
Max Phase: 3.0
Molecule Type: Antibody

Molecule: MEDI-565
ChEMBL ID: CHEMBL2109372
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 1.0
Molecule Type: Antibody

Molecule: RESIMMUNE
ChEMBL ID: CHEMBL4297555
Mechanism of Action: BINDING AGENT
Max Phase: 2.0
Molecule Type: Unknown

Molecule: MUROMONAB-CD3
ChEMBL ID: CHEMBL1201608
Mechanism of Action: INHIBITOR
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 1986

Molecule: BLINATUMOMAB
ChEMBL ID: CHEMBL1742992
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2014

Molecule: FORALUMAB
ChEMBL ID: CHEMBL1743020
Mechanism of Action: INHIBITOR
Max Phase: 2.0
Molecule Type: Antibody

Molecule: CATUMAXOMAB
ChEMBL ID: CHEMBL2108581
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2009

Molecule: SOLITOMAB
ChEMBL ID: CHEMBL2109264
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 2.0
Molecule Type: Antibody

Molecule: IMC-GP100
ChEMBL ID: CHEMBL2109434
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: -1.0
Molecule Type: Antibody

Molecule: FBT-A05
ChEMBL ID: CHEMBL2109351
Mechanism of Action: CROSS-LINKING AGENT
Max Phase: 1.0
Molecule Type: Antibody

Molecule: FLOTETUZUMAB
ChEMBL ID: CHEMBL3990038
Mechanism of Action: BINDING AGENT
Max Phase: 2.0
Molecule Type: Antibody

Molecule: ELRANATAMAB
ChEMBL ID: CHEMBL4297809
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2023

Molecule: TECLISTAMAB
ChEMBL ID: CHEMBL4594505
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2022

Molecule: TALQUETAMAB
ChEMBL ID: CHEMBL4594503
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2023

Molecule: EPCORITAMAB
ChEMBL ID: CHEMBL4650393
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2023

Molecule: GLOFITAMAB
ChEMBL ID: CHEMBL4298092
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2023

Molecule: MOSUNETUZUMAB
ChEMBL ID: CHEMBL4297788
Mechanism of Action: BINDING AGENT
Max Phase: 4.0
Molecule Type: Antibody
First Approval: 2022

Molecule: ODRONEXTAMAB
ChEMBL ID: CHEMBL4298084
Mechanism of Action: BINDING AGENT
Max Phase: 2.0
Molecule Type: Antibody
